vs

Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and Ribbon Communications Inc. (RBBN). Click either name above to swap in a different company.

Ribbon Communications Inc. is the larger business by last-quarter revenue ($162.6M vs $154.2M, roughly 1.1× BridgeBio Pharma, Inc.). Ribbon Communications Inc. runs the higher net margin — 54.8% vs -126.2%, a 181.0% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs -10.3%).

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...

Ribbon Communications Inc. is a public company that makes software, IP and optical networking solutions for service providers, enterprises and critical infrastructure sectors. The company was formed in 2017, following the merger of Genband and Sonus Networks and is headquartered in Plano, Texas.

BBIO vs RBBN — Head-to-Head

Bigger by revenue
RBBN
RBBN
1.1× larger
RBBN
$162.6M
$154.2M
BBIO
Growing faster (revenue YoY)
BBIO
BBIO
+2531.5% gap
BBIO
2521.2%
-10.3%
RBBN
Higher net margin
RBBN
RBBN
181.0% more per $
RBBN
54.8%
-126.2%
BBIO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BBIO
BBIO
RBBN
RBBN
Revenue
$154.2M
$162.6M
Net Profit
$-194.6M
$89.1M
Gross Margin
94.7%
42.9%
Operating Margin
-90.5%
37.6%
Net Margin
-126.2%
54.8%
Revenue YoY
2521.2%
-10.3%
Net Profit YoY
27.2%
EPS (diluted)
$-1.00
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBIO
BBIO
RBBN
RBBN
Q1 26
$162.6M
Q4 25
$154.2M
$227.3M
Q3 25
$120.7M
$215.4M
Q2 25
$110.6M
$220.6M
Q1 25
$116.6M
$181.3M
Q4 24
$251.4M
Q3 24
$210.2M
Q2 24
$192.6M
Net Profit
BBIO
BBIO
RBBN
RBBN
Q1 26
$89.1M
Q4 25
$-194.6M
Q3 25
$-184.9M
$-12.1M
Q2 25
$-183.8M
$-11.1M
Q1 25
$-169.6M
$-26.2M
Q4 24
Q3 24
$-13.4M
Q2 24
$-16.8M
Gross Margin
BBIO
BBIO
RBBN
RBBN
Q1 26
42.9%
Q4 25
94.7%
53.3%
Q3 25
94.6%
50.1%
Q2 25
96.7%
49.6%
Q1 25
97.7%
45.4%
Q4 24
55.7%
Q3 24
52.1%
Q2 24
50.8%
Operating Margin
BBIO
BBIO
RBBN
RBBN
Q1 26
37.6%
Q4 25
-90.5%
4.1%
Q3 25
-120.3%
1.3%
Q2 25
-121.4%
1.9%
Q1 25
-89.5%
-10.8%
Q4 24
13.2%
Q3 24
-0.4%
Q2 24
-1.0%
Net Margin
BBIO
BBIO
RBBN
RBBN
Q1 26
54.8%
Q4 25
-126.2%
Q3 25
-153.2%
-5.6%
Q2 25
-166.2%
-5.0%
Q1 25
-145.4%
-14.5%
Q4 24
Q3 24
-6.4%
Q2 24
-8.7%
EPS (diluted)
BBIO
BBIO
RBBN
RBBN
Q1 26
$0.50
Q4 25
$-1.00
$0.50
Q3 25
$-0.95
$-0.07
Q2 25
$-0.95
$-0.06
Q1 25
$-0.88
$-0.15
Q4 24
$0.05
Q3 24
$-0.08
Q2 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBIO
BBIO
RBBN
RBBN
Cash + ST InvestmentsLiquidity on hand
$570.1M
$67.6M
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$-2.1B
$419.1M
Total Assets
$936.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBIO
BBIO
RBBN
RBBN
Q1 26
$67.6M
Q4 25
$570.1M
$96.4M
Q3 25
$643.0M
$74.8M
Q2 25
$756.9M
$60.5M
Q1 25
$540.6M
$71.2M
Q4 24
$87.8M
Q3 24
$37.2M
Q2 24
$64.6M
Total Debt
BBIO
BBIO
RBBN
RBBN
Q1 26
Q4 25
$2.0B
$342.1M
Q3 25
$2.0B
$344.3M
Q2 25
$346.5M
Q1 25
$347.4M
Q4 24
$348.3M
Q3 24
$349.1M
Q2 24
$350.0M
Stockholders' Equity
BBIO
BBIO
RBBN
RBBN
Q1 26
$419.1M
Q4 25
$-2.1B
$449.0M
Q3 25
$-1.9B
$360.1M
Q2 25
$-1.8B
$370.4M
Q1 25
$-1.6B
$381.8M
Q4 24
$404.6M
Q3 24
$395.5M
Q2 24
$405.0M
Total Assets
BBIO
BBIO
RBBN
RBBN
Q1 26
Q4 25
$936.0M
$1.2B
Q3 25
$998.3M
$1.1B
Q2 25
$1.1B
$1.1B
Q1 25
$881.6M
$1.1B
Q4 24
$1.2B
Q3 24
$1.1B
Q2 24
$1.1B
Debt / Equity
BBIO
BBIO
RBBN
RBBN
Q1 26
Q4 25
0.76×
Q3 25
0.96×
Q2 25
0.94×
Q1 25
0.91×
Q4 24
0.86×
Q3 24
0.88×
Q2 24
0.86×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBIO
BBIO
RBBN
RBBN
Operating Cash FlowLast quarter
$-56.4M
Free Cash FlowOCF − Capex
$-56.5M
FCF MarginFCF / Revenue
-36.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBIO
BBIO
RBBN
RBBN
Q1 26
Q4 25
$-56.4M
$29.2M
Q3 25
$-109.6M
$26.5M
Q2 25
$-80.7M
$-795.0K
Q1 25
$-199.2M
$-3.5M
Q4 24
$61.8M
Q3 24
$-14.8M
Q2 24
$-9.8M
Free Cash Flow
BBIO
BBIO
RBBN
RBBN
Q1 26
Q4 25
$-56.5M
$27.3M
Q3 25
$-110.0M
$21.0M
Q2 25
$-81.3M
$-6.5M
Q1 25
$-15.7M
Q4 24
$53.8M
Q3 24
$-23.7M
Q2 24
$-12.9M
FCF Margin
BBIO
BBIO
RBBN
RBBN
Q1 26
Q4 25
-36.6%
12.0%
Q3 25
-91.2%
9.7%
Q2 25
-73.5%
-2.9%
Q1 25
-8.7%
Q4 24
21.4%
Q3 24
-11.3%
Q2 24
-6.7%
Capex Intensity
BBIO
BBIO
RBBN
RBBN
Q1 26
Q4 25
0.0%
0.9%
Q3 25
0.4%
2.6%
Q2 25
0.5%
2.6%
Q1 25
0.0%
6.7%
Q4 24
3.2%
Q3 24
4.2%
Q2 24
1.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBIO
BBIO

Segment breakdown not available.

RBBN
RBBN

Service$94.5M58%
Product$68.1M42%

Related Comparisons